The agenda includes:
Preparation of positions on the evaluation of drugs:
- Sarclisa (Isatuxima) under the drug programme “Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)”,
- Trixeo (aerosphere) for the indication: maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated with a combination of an inhaled corticosteroid with a long-acting β2-receptor agonist or a combination of a β2-receptor agonist with a long-acting muscarinic receptor antagonist,
- Enhertu (trastuzumab deruxtecan) under a drug programme “Treatment of patients with breast cancer with trastuzumab deruxtecan (ICD-10 C50)”.
Preparing an opinion on the legitimacy of introducing changes in the B.9 drug programme. “Treatment of patients with breast cancer (ICD-10: C50)”.
Preparation of an opinion on the comparison of HPV vaccines.